The FDA approved Moderna’s lower-dose COVID-19 vaccine, but only for individuals aged 65 years or older and people aged 12 to ...

The new mRNA vaccine encodes the receptor-binding domain and the N-terminal domain of the SARS-CoV-2 spike protein ...

CHENNAI: The US Food and Drug Administration (FDA) on Saturday officially approved Moderna’s next-generation COVID-19 vaccine ...

The Food and Drug Administration (FDA) has approved Moderna's next-generation COVID-19 vaccine, mNEXSPIKE, for specific ...

The Food and Drug administration has approved a new COVID-19 vaccine made by Moderna but with limits on who can use it ...

The Food and Drug Administration approved Moderna's next-generation COVID-19 vaccine for adults 65 and older, the company ...

But the FDA will encourage drugmakers to commit to conducting post-marketing clinical trials in healthy adults when the agency approves covid vaccines for those populations. For the past five ...

That's a major change from the current approach, which recommends and approves ... The FDA estimates 100 million to 200 million Americans would be eligible for COVID vaccines under the new approach.

The companies that make COVID-19 vaccines should update ... would not appear to make a difference in how the FDA approves the next vaccines. The new strategy would continue the current vaccine ...